Important News & Announcements

Stay up to date with the latest news and announcements from NASCSA.

Back to all news

LA PMP Guidance: The Reporting of Accurate Prescriber Info

Posted 9/29/2021

The Board's Compliance Officers have been conducting on-site audits of pharmacy prescription records. The audits are being conducted to ensure complete and accurate reporting to the PMP. As a result of audit findings, the following guidance has been developed. For controlled substance prescriptions, the prescriber's DEA registration number is a required element of the prescription and must be reported to the PMP. It is of the utmost importance that pharmacists do not use a fake prescriber DEA registration number or fake prescriber NPI number on any prescription transaction, only use accurate information. For non-controlled substance prescriptions which are drugs of concern (e.g., gabapentin) and the prescriber does not possess a DEA registration number, the DEA field should be left blank and the prescriber NPI field reported. If the prescriber is a veterinarian who does not possess a DEA or NPI number, both fields should be left blank and the veterinarian's numerical license number from the Louisiana Board of Veterinary Medicine should be entered in the prescriber's state license number field and the transaction reported. For prescriptions in which the prescriber uses a hospital's DEA registration number, in conformance with 21 CFR 1301.22(c), the hospital's DEA registration number with the prescriber's hospital assigned suffix and the prescriber's name must be reported to the PMP. 

Sincerely,

Joe Fontenot
Executive Director
Designate Louisiana Board of Pharmacy

Back to all news

Sponsor Spotlight

COMPASS Pathways


COMPASS Pathways is delighted to be a sponsor of NASCSA and looks forward to both engaging with controlled substances authorities, NASCSA leadership, and members to learn about their important work, and educate about our company's mission and the innovations underway using novel therapies.

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments.

We are developing innovative therapies and, when appropriate, combining them with psychological support and next-generation digital tools to forge new, sustainable mental health care pathways.

Our investigational COMP360 psilocybin therapy is currently undergoing phase 3 investigation in treatment-resistant depression. We are also assessing COMP360 in anorexia nervosa and post-traumatic stress disorder, across multiple clinical studies.

Learn more https://www.compasspathways.com

All Sponsors